Expression and clinical significance of PD-1/PD-Ls in EBV-positive T/NK lymphoprolif-erative disorders
10.3969/j.issn.1000-8179.2018.24.030
- VernacularTitle:PD-1/PD-Ls在EBV阳性T/NK淋巴组织增殖性疾病中的表达及临床意义*
- Author:
Junxia HU
1
,
2
;
Qingjiang CHEN
;
Xudong ZHANG
;
Wencai LI
;
Guannan WANG
;
Xin WANG
;
Meng DONG
;
Shaoxuan WU
;
Mijing MA
;
Meifeng YIN
;
Wanqiu YANG
;
Mengjie DING
;
Mingzhi ZHANG
;
Linan ZHU
Author Information
1. 郑州大学第一附属医院肿瘤内科(郑州市450052)
2. 郑州大学第一附属医院淋巴瘤诊疗中心(郑州市450052)
- Keywords:
Epstein-Barr virus (EBV);
lymphoproliferative disease;
programmed cell death protein 1 (PD-1);
programmed death-ligand 1 (PD-L1);
programmed death-ligand 2 (PD-L2)
- From:
Chinese Journal of Clinical Oncology
2018;45(24):1248-1253
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the expression and clinical significance of programmed death-ligand 1 (PD-L1), programmed death-ligand 2 (PD-L2), and their receptor programmed cell death protein 1 (PD-1) in EBV-positive T/NK lymphoproliferative disease [Epstein-Barr virus-positive T/natural killer (NK)-cell lymphoproliferative disease, EBV(+)-T/NK-LPD]. Methods: The pathological paraffin-embedded tissues of 17 patients with EBV(+)-T/NK-LPD from the First Affiliated Hospital of Zhengzhou University from January 2013 to December 2017 were collected. These patients include 12 males and 5 females, aged 10-82 years old, the average age being 29 years, 4 people in gradeⅠ, 7 in gradeⅡ, 3 in gradeⅢ, and 3 people with hydroa vacciniforme-like lymphoproliferative disorders. Immunohistochemical SP method was used to detect the expression of PD-1, PD-L1, and PD-L2 in human EBV(+)-T/NK-LPD tissues. The relationship between PD-1, PD-L1, PD-L2 expression, and clinicopathological parameters, pathological grades and prognosis were analyzed by Fisher's exact probabilities and Spearman rank correlation. Result: After statistical analysis, the results showed that in 17 cases of tissue samples, there were 12 cases with positive PD-1 expression, 6 cases with positive PD-L1 expression and 5 cases with positive PD-L2 expression. There was no significant correlation between PD-1 and PD-L2 expression and prognosis (P>0.05). PD-L1 expression showed a positive correlation with prognosis (P<0.05). There was no significant correlation between the expression of PD-L1 and PD-L2 with age, sex, as well as LDH and Ki-67 levels (P>0.05). Moreover, there was no significant correlation of PD-1 and PD-L2 expression with pathological grade (r=0.141, r=-0.149, both P>0.05). However, there was a negative correlation between the PD-L1 expression and pathological grade (r=-0.563), and the correlation between the PD-L1 ex-pression and pathological grade was statistically significant (P<0.05). Conclusions: PD-1, PD-L1, and PD-L2 are abnormally expressed in the pathological tissues of EBV(+)-T/NK-LPD. Although there was no significant correlation between the expression of PD-1 and prognosis or pathological grade, it was significantly higher in EBV+T/NK-LPD. PD-1/PD-Ls associated signaling pathway is expected to be a potential new target for EBV(+)-T/NK-LPD immunotherapy.
